This study is not yet accepting patients
Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
a study on Transitional Cell Carcinoma
Urothelial Carcinoma Recurrent Advanced Urothelial Carcinoma Carcinoma Carcinoma, Transitional Cell Durvalumab Vactosertib(TEW-7197)/ Durvalumab Vactosertib+Durvalumab
Lead Scientist at UCSF
- Lawrence Fong, MD
Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at the UCSF. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity Program in the Helen Diller Family Comprehensive Cancer Center.
- not yet accepting patients
- Start Date
- Completion Date
- MedPacto, Inc.
- Phase 2
- Study Type
- Last Updated